AEON Biopharma, a clinical-stage biopharmaceutical company, went public via a SPAC merger with Priveterra Acquisition, a blank cheque company, in a $475m deal. “We are grateful to all investors that continue to support Priveterra’s investment thesis in combining with AEON, along with their significant contributions of up to $125 million in arranged funding. I look forward to continuing my journey with AEON," Robert Palmisano, Priveterra Acquisition Chairman and CEO.